eCoin® is an electroceutical, which is a radically small neurostimulator that stimulates nerves in the periphery to ameliorate chronic conditions.

Valencia is led by Jeff Greiner, who built Advanced Bionics (AB) from seven engineers and no revenues into a company with 2,500 employees and revenues exceeding $300 million. AB was sold to two different companies for over $3 billion—final sale in 2010. Board Member and Architect of eCoin, Dave Peterson, led the design of Medtronic’s first dual chamber ICD; won every major technical award given by Medtronic including the Bakken; and then was recruited by Greiner to design AB’s spinal cord stimulator. This product, now sold by Boston Scientific Neuromodulation, for which it paid AB shareholders $2.5 billion, will generate over $500 million in revenue this year for Boston.

The history of neuromodulation is based on constant stimulation of a nerve to effect some good.  Valencia challenges that fundamental assumption with its invention that is fully developed, is being manufactured, and is now in clinical trials.

Based on low-duty cycle, non-constant stimulation, Valencia invented a tiny, coin-sized and shaped neurostimulator to be placed subcutaneously in a short office or outpatient procedure.  No more lead-wires to be tunneled to the target from a remote fatty pocket holding the electronics.  Valencia’s electroceutical is placed just over the target.

Today, Valencia has more than thirty issued patents for its innovative ideas and over a dozen patent applications pending.

Valencia’s Electroceutical Coin (eCoin®) is a foundational technology similar to the building block compounds of major biotechnology companies. Sharing the desirable business characteristics of biotechnology such as large market opportunity, multiple assets, and low cost of goods sold to price ratio, eCoin combines the opportunity of biotechnology with limited risks of medtech.

Please fill out the form below if you have questions about Valencia Technologies or eCoin.